


## Angiogenic Healing Cycle



### Myocardial-Derived Growth Factor Therapeutics

*"New Biological Tools for the Highly Innovative and Rapidly Growing Interventional Cardiology Market"*

Generx™ is designed as a one-time angiogenic therapy, which can be administered by interventional cardiologists to promote and stimulate the natural growth of collateral circulation that supplies blood flow to the myocardium. These therapeutic effects are mediated by DNA-coded myocardial-derived FGF-4 growth factor proteins that can promote angiogenesis and collateral circulation to thereby relieve recurrent angina associated with ischemic heart disease. We believe Generx has been one of the most widely studied and clinically most advanced DNA-based cardiovascular angiogenic growth factor therapeutics in the world. It has already been evaluated in studies of approximately 663 patients in four multi-center, double-blind, placebo-controlled clinical studies. These studies have been conducted at over 70 U.S., Canadian, European and South American medical centers.

